Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 94,854 shares of the company’s stock after selling 1,325 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Roivant Sciences were worth $1,122,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ROIV. Nordea Investment Management AB lifted its stake in Roivant Sciences by 22.5% during the 4th quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock worth $3,306,000 after acquiring an additional 52,031 shares in the last quarter. TOMS Capital Investment Management LP purchased a new position in Roivant Sciences in the 3rd quarter valued at approximately $46,333,000. Barclays PLC boosted its position in Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after buying an additional 75,609 shares during the period. Retirement Systems of Alabama grew its stake in shares of Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock worth $6,116,000 after acquiring an additional 112,286 shares in the last quarter. Finally, Elevate Capital Advisors LLC acquired a new stake in shares of Roivant Sciences in the fourth quarter valued at $2,116,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the purchase, the director now owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Eric Venker sold 176,900 shares of the company’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00. Following the completion of the transaction, the chief operating officer now owns 668,680 shares in the company, valued at approximately $7,903,797.60. This trade represents a 20.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,750,145 shares of company stock valued at $19,170,200. Corporate insiders own 7.90% of the company’s stock.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $10.44 on Thursday. Roivant Sciences Ltd. has a 1 year low of $9.96 and a 1 year high of $13.06. The company has a market capitalization of $7.45 billion, a PE ratio of -69.60 and a beta of 1.26. The company has a fifty day moving average of $10.77 and a two-hundred day moving average of $11.43.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, research analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on ROIV. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Roivant Sciences currently has an average rating of “Buy” and a consensus price target of $17.10.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.